Items Tagged ‘News’

December 8th, 2016

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?

By

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO). Currently, HER2 is the only marker that can be […]

View full entry

Tags: adenocarcinoma, American Society for Clinical Pathology, and American Society of Clinical Oncology, asco, ASCP, CAP, College of American Pathologists, Esophageal Cancer, for human epidermal growth factor receptor 2, Gastric Cancer, Gastroesophageal cancer, HER2 testing


December 5th, 2016

ASCO Recommends Early Integration of Palliative Care for Advanced Cancers

By

The American Society of Clinical Oncology (ASCO) has updated its guidelines on the integration of palliative care for patients diagnosed with advanced cancer, as well as their caretakers. In essence, the guidelines state that palliative care should be administered as early as possible for all patients diagnosed with advanced cancers, alongside their active treatment, as […]

View full entry

Tags: active treatment, advanced cancer, All Cancer Types, asco, caregiver, guidelines, News, Palliative care, quality of life, Types of Cancer


December 5th, 2016

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

By

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of […]

View full entry

Tags: AXL, Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, MET, metastatic, mRCC, News, Renal Cancer, sunitinib, Sutent


December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

By

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or […]

View full entry

Tags: Blood transfusions, Hodgkin's Lymphoma, Leukemia, long-term, Multiple Myeloma, Myeloproliferative Neoplasms MPN, News, Non-Hodgkin's Lymphoma, short-term, storage


November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


November 28th, 2016

Opdivo Approved for Advanced Head and Neck Cancer

By

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the head and neck cancer (SCCHN) that has spread to distant sites in the body and has progressed or […]

View full entry

Tags: fda, General Head and Neck Cancer, Head and Neck Cancer, News, nivolumab, opdivo, schhn


November 20th, 2016

It’s GERD Awareness Week–November 20th

By

It’s that time of year again when there is a tendency to overindulge in a mélange of delicious foods. Although many people may only suffer discomfort from over eating, another group of people suffer from the far more troublesome and chronic disorder of GERD—and it isn’t just over the holidays, nor is it simply from […]

View full entry

Tags: barrett's esophagus, Esophageal Cancer, GERD, heartburn, News, online community, Screening/Prevention Esophageal Cancer


November 17th, 2016

FDA Priority Review Granted for Midostaurin in Leukemia

By

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The diagnostic test to detect the FLT3 mutation has also been accepted for review by […]

View full entry

Tags: Acute Myeloid Leukemia, AML, fda, FLT3 mutation, itchy skin, Leukemia, mast cell, mastocytosis, midostaurin, News, PKC412


November 15th, 2016

Aromatase Inhibitor–Associated Joint Pain Tends to Resolve Upon Treatment Completion

By

A class of drugs known as aromatase inhibitors (AI) commonly used in the management of estrogen receptor-positive (ER+) breast cancer are associated with troublesome joint pain. In fact, as many as half of women on AI therapy experience joint pain, and 20% become non-compliant with their AI therapy because of side effects.1 The origin of […]

View full entry

Tags: AI, aromatase inhibitors, Breast Cancer, ER-positive, joint pain, News


November 9th, 2016

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer

By

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to cancer progression for Lynparza-treated patients […]

View full entry

Tags: AstraZeneca, BRACAnalysis CDx, brca, lynparza, News, olaprarib, Ovarian Cancer, PARP enzyme, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


November 8th, 2016

Inflammatory Bowel Disease: More Common than Previously Thought

By

A recent report reveals that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), effect an estimated 3.1 million (1.3%) U.S. adults.  This is an increase from a report released in 1999 estimating that 1.8 million Americans (0.9%) were diagnosed with IBD. IBD is an immune-mediated chronic inflammation of the gastrointestinal tract. […]

View full entry

Tags: Colon Cancer, crohn's, crohn's disease, ibd, irritable bowel disease, News, Screening/Prevention Colon Cancer, uc, ulcerative colitis


November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


November 7th, 2016

Chemotherapy Before Surgery Improves Treatment of Sarcoma

By

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is called neoadjuvant therapy and has not previously been demonstrated to improve outcomes in soft tissue sarcoma (STS). Soft tissue […]

View full entry

Tags: anthracycline, dacarbazine, epirubicin, for undifferentiated pleomorphic sarcoma, gemcitabine, ifosfamide, leiomyosarcoma, malignant peripheral nerve sheath tumors, neoadjuvant therapy, News, Sarcoma, soft tissue sarcoma


October 31st, 2016

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

By

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP […]

View full entry

Tags: BRCA1, BRCA2, lynparza, News, niraparib, olaparib, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine